liu.seSök publikationer i DiVA
Ändra sökning
Avgränsa sökresultatet
1 - 6 av 6
RefereraExporteraLänk till träfflistan
Permanent länk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Träffar per sida
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sortering
  • Standard (Relevans)
  • Författare A-Ö
  • Författare Ö-A
  • Titel A-Ö
  • Titel Ö-A
  • Publikationstyp A-Ö
  • Publikationstyp Ö-A
  • Äldst först
  • Nyast först
  • Skapad (Äldst först)
  • Skapad (Nyast först)
  • Senast uppdaterad (Äldst först)
  • Senast uppdaterad (Nyast först)
  • Disputationsdatum (tidigaste först)
  • Disputationsdatum (senaste först)
  • Standard (Relevans)
  • Författare A-Ö
  • Författare Ö-A
  • Titel A-Ö
  • Titel Ö-A
  • Publikationstyp A-Ö
  • Publikationstyp Ö-A
  • Äldst först
  • Nyast först
  • Skapad (Äldst först)
  • Skapad (Nyast först)
  • Senast uppdaterad (Äldst först)
  • Senast uppdaterad (Nyast först)
  • Disputationsdatum (tidigaste först)
  • Disputationsdatum (senaste först)
Markera
Maxantalet träffar du kan exportera från sökgränssnittet är 250. Vid större uttag använd dig av utsökningar.
  • 1.
    Aerts, Joel
    et al.
    University of Liege, Belgium; University of Paris 07, France.
    Ballinger, James R.
    Guy's and St Thomas' Hospital, London, UK.
    Behe, Martin
    ETH PSI USZ Paul Scherrer Institute, Villigen-PSI, Switzerland.
    Decristoforo, Clemens
    Innsbruck Medical University, Austria.
    Elsinga, Philip H.
    University of Groningen, Netherlands.
    Faivre-Chauvet, Alain
    CHU Nantes, France.
    Mindt, Thomas L.
    University Hospital Basel, Switzerland.
    Kolenc Peitl, Petra
    University Medical Centre Ljubljana, Slovenia.
    Todde, Sergio C.
    University of Milano-Bicocca, Italy.
    Koziorowski, Jacek
    Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för radiologiska vetenskaper. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Centrum för kirurgi, ortopedi och cancervård, Radiofysikavdelningen US.
    Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective2014Ingår i: Journal of labelled compounds & radiopharmaceuticals, ISSN 0362-4803, E-ISSN 1099-1344, Vol. 57, nr 10, s. 615-620Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    This document is meant to complement Part B of the EANM Guidelines on current good radiopharmacy practice (cGRPP) in the preparation of radiopharmaceuticals issued by the Radiopharmacy Committee of the European Association of Nuclear Medicine, covering small-scale in-house preparation of radiopharmaceuticals with automated modules. The aim is to provide more detailed and practice-oriented guidance to those who are involved in the small-scale preparation of radiopharmaceuticals, which are not intended for commercial purposes or distribution.

  • 2.
    Bernhardsson, Magnus
    et al.
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Avdelningen för Kirurgi, Ortopedi och Onkologi. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Centrum för kirurgi, ortopedi och cancervård, Ortopedkliniken i Linköping.
    Sandberg, Olof
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Avdelningen för Kirurgi, Ortopedi och Onkologi. Linköpings universitet, Medicinska fakulteten. Linköpings universitet, Institutionen för medicin och hälsa. Region Östergötland, Centrum för kirurgi, ortopedi och cancervård, Ortopedkliniken i Linköping.
    Ressner, Marcus
    Linköpings universitet, Institutionen för medicin och hälsa. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Diagnostikcentrum, Medicinsk strålningsfysik.
    Koziorowski, Jacek
    Linköpings universitet, Medicinska fakulteten. Region Östergötland, Diagnostikcentrum, Röntgenkliniken i Linköping. Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för radiologiska vetenskaper.
    Malmqvist, Jonas
    Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för radiologiska vetenskaper. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Diagnostikcentrum, Röntgenkliniken i Linköping.
    Aspenberg, Per
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Avdelningen för Kirurgi, Ortopedi och Onkologi. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Centrum för kirurgi, ortopedi och cancervård, Ortopedkliniken i Linköping.
    Shining dead bone-cause for cautious interpretation of [F-18]NaF PET scans2018Ingår i: Acta Orthopaedica, ISSN 1745-3674, E-ISSN 1745-3682, Vol. 89, nr 1, s. 124-127Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Background and purpose — [18F]Fluoride ([18F]NaF) PET scan is frequently used for estimation of bone healing rate and extent in cases of bone allografting and fracture healing. Some authors claim that [18F]NaF uptake is a measure of osteoblastic activity, calcium metabolism, or bone turnover. Based on the known affinity of fluoride to hydroxyapatite, we challenged this view.

    Methods — 10 male rats received crushed, frozen allogeneic cortical bone fragments in a pouch in the abdominal wall on the right side, and hydroxyapatite granules on left side. [18F]NaF was injected intravenously after 7 days. 60 minutes later, the rats were killed and [18F]NaF uptake was visualized in a PET/CT scanner. Specimens were retrieved for micro CT and histology.

    Results — MicroCT and histology showed no signs of new bone at the implant sites. Still, the implants showed a very high [18F]NaF uptake, on a par with the most actively growing and remodeling sites around the knee joint.

    Interpretation — [18F]NaF binds with high affinity to dead bone and calcium phosphate materials. Hence, an [18F]NaF PET/CT scan does not allow for sound conclusions about new bone ingrowth into bone allograft, healing activity in long bone shaft fractures with necrotic fragments, or remodeling around calcium phosphate coated prostheses

  • 3.
    Joshi, Sameer M.
    et al.
    CIC BiomaGUNE, Spain.
    de Cozar, Abel
    University of Basque Country, Spain; Ikerbasque, Spain; Centre Innovac Quim Avanzada ORFEO CINQA, Spain; DIPC, Spain.
    Gomez-Vallejo, Vanessa
    CIC BiomaGUNE, Spain.
    Koziorowski, Jacek
    Linköpings universitet, Institutionen för medicin och hälsa. Region Östergötland, Centrum för kirurgi, ortopedi och cancervård, Radiofysikavdelningen US. Linköpings universitet, Medicinska fakulteten.
    Llop, Jordi
    CIC BiomaGUNE, Spain.
    Cossio, Fernando P.
    University of Basque Country, Spain; Centre Innovac Quim Avanzada ORFEO CINQA, Spain.
    Synthesis of radiolabelled aryl azides from diazonium salts: experimental and computational results permit the identification of the preferred mechanism2015Ingår i: Chemical Communications, ISSN 1359-7345, E-ISSN 1364-548X, Vol. 51, nr 43, s. 8954-8957Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Experimental and computational studies on the formation of aryl azides from the corresponding diazonium salts support a stepwise mechanism via acyclic zwitterionic intermediates. The low energy barriers associated with both transition structures are compatible with very fast and efficient processes, thus making this method suitable for the chemical synthesis of radiolabelled aryl azides.

  • 4.
    Taldone, Tony
    et al.
    Mem Sloan Kettering Cancer Centre, NY 10065 USA.
    Zatorska, Danuta
    Mem Sloan Kettering Cancer Centre, NY 10065 USA.
    Ochiana, Stefan O.
    Mem Sloan Kettering Cancer Centre, NY 10065 USA.
    Smith-Jones, Peter
    Mem Sloan Kettering Cancer Centre, NY 10065 USA; Stony Brook School Med, NY USA; Stony Brook School Med, NY USA.
    Koziorowski, Jacek
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York,NY, USA.
    Dunphy, Mark P.
    Mem Sloan Kettering Cancer Centre, NY 10065 USA.
    Zanzonico, Pat
    Mem Sloan Kettering Cancer Centre, NY 10065 USA.
    Bolaender, Alexander
    Mem Sloan Kettering Cancer Centre, NY 10065 USA.
    Lewis, Jason S.
    Mem Sloan Kettering Cancer Centre, NY 10065 USA; Mem Sloan Kettering Cancer Centre, NY 10065 USA.
    Larson, Steven M.
    Mem Sloan Kettering Cancer Centre, NY 10065 USA; Mem Sloan Kettering Cancer Centre, NY 10065 USA.
    Chiosis, Gabriela
    Mem Sloan Kettering Cancer Centre, NY 10065 USA.
    Vara Kishore Pillarsetty, Naga
    Mem Sloan Kettering Cancer Centre, NY 10065 USA.
    Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H712016Ingår i: Journal of labelled compounds & radiopharmaceuticals, ISSN 0362-4803, E-ISSN 1099-1344, Vol. 59, nr 3, s. 129-132Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Heat shock protein 90 (Hsp90) is an ATP dependent molecular chaperone protein whose function is critical for maintaining several key proteins involved in survival and proliferation of cancer cells. PU-H71 (1), is a potent purine-scaffold based ATP pocket binding Hsp90 inhibitor which has been shown to have potent activity in a broad range of in vivo cancer models and is currently in Phase I clinical trials in patients with advanced solid malignancies, lymphomas, and myeloproliferative neoplasms. In this report, we describe the radiosynthesis of [I-124]-PU-H71(5); this was synthesized from the corresponding Boc-protected stannane precursor 3 by iododestannylation with [I-124]-NaI using chloramine-T as an oxidant for 2min, followed by Boc deprotection with 6 N HCl at 50 degrees C for 30min to yield the final compound. The final product 5 was purified using HPLC and was isolated with an overall yield of 55 +/- 6% (n=6, isolated) from 3, and >98% purity and an average specific activity of 980mCi/mu mol. Our report sets the stage for the introduction of [I-124]-PU-H71 as a potential non-invasive probe for understanding biodistribution and pharmacokinetics of PU-H71 in living subjects using positron emission tomography imaging.

  • 5.
    Todde, S.
    et al.
    University of Milano-Bicocca, Tecnomed Foundation, Italy.
    Peitl, P. Kolenc
    Department of Nuclear Medicine, University Medical Centre Ljubljana, Slovenia.
    Elsinga, P.
    University Medical Center Groningen, University of Groningen, The Netherlands.
    Koziorowski, Jacek
    Linköpings universitet, Institutionen för medicin och hälsa. Region Östergötland, Centrum för kirurgi, ortopedi och cancervård, Radiofysikavdelningen US. Linköpings universitet, Medicinska fakulteten.
    Ferrari, V.
    GE Healthcare, Amersham, UK.
    Ocak, E. M.
    Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul University, Istanbul Turkey.
    Hjelstuen, O.
    Institute for Energy Technology, Norway.
    Patt, M.
    Department for Nuclear Medicine, Radiochemistry, Leipzig, Germany.
    Mindt, T. L.
    Ludwig Boltzmann Institute Applied Diagnostics, General Hospital Vienna, Nuklearmedizin, Vienna, Austria; 10Department of Biomedical Imaging and Image Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
    Behe, M.
    Center for Radiopharmaceutical Sciences ETH-PSI-USZ Paul-Scherrer-Institute, Switzerland.
    Guidance on validation and qualification of processes and operations involving radiopharmaceuticals2017Ingår i: EJNMMI radiopharmacy and chemistry, ISSN 2365-421X, Vol. 2, nr 1Artikel, forskningsöversikt (Refereegranskat)
    Abstract [en]

    Validation and qualification activities are nowadays an integral part of the day by day routine work in a radiopharmacy. This document is meant as an Appendix of Part B of the EANM "Guidelines on Good Radiopharmacy Practice (GRPP)" issued by the Radiopharmacy Committee of the EANM, covering the qualification and validation aspects related to the small-scale "in house" preparation of radiopharmaceuticals. The aim is to provide more detailed and practice-oriented guidance to those who are involved in the small-scale preparation of radiopharmaceuticals which are not intended for commercial purposes or distribution.

  • 6.
    Todde, Sergio
    et al.
    University of Milano Bicocca, Italy.
    Windhorst, Albert D.
    Vrije University of Amsterdam, Netherlands.
    Behe, Martin
    ETH PSI USZ, Switzerland.
    Bormans, Guy
    Katholieke University of Leuven, Belgium.
    Decristoforo, Clemens
    Medical University of Innsbruck, Austria.
    Faivre-Chauvet, Alain
    CHU Nantes, France.
    Ferrari, Valentina
    GE Healthcare, England.
    Gee, Antony D.
    Kings Coll London, England.
    Gulyas, Balazs
    Karolinska Institute, Sweden.
    Halldin, Christer
    Karolinska Institute, Sweden.
    Kolenc Peitl, Petra
    University of Medical Centre Ljubljana, Slovenia.
    Koziorowski, Jacek
    Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för radiologiska vetenskaper. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Centrum för kirurgi, ortopedi och cancervård, Radiofysikavdelningen US.
    Mindt, Thomas L.
    University of Basel Hospital, Switzerland.
    Sollini, Martina
    Arcispedale Santa Maria Nuova, Italy.
    Vercouillie, Johnny
    University of Tours, France.
    Ballinger, James R.
    Guys and St Thomas Hospital, England.
    Elsinga, Philip H.
    University of Groningen, Netherlands.
    EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)2014Ingår i: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 41, nr 11, s. 2175-2185Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    The preparation of an Investigational Medicinal Product Dossier (IMPD) for a radiopharmaceutical to be used in a clinical trial is a challenging proposition for radiopharmaceutical scientists working in small-scale radiopharmacies. In addition to the vast quantity of information to be assembled, the structure of a standard IMPD is not well suited to the special characteristics of radiopharmaceuticals. This guideline aims to take radiopharmaceutical scientists through the practicalities of preparing an IMPD, in particular giving advice where the standard format is not suitable. Examples of generic IMPDs for three classes of radiopharmaceuticals are given: a small molecule, a kit-based diagnostic test and a therapeutic radiopharmaceutical.

1 - 6 av 6
RefereraExporteraLänk till träfflistan
Permanent länk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf